Market closed
Zentalis Pharmaceuticals/$ZNTL
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Zentalis Pharmaceuticals
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. It uses a drug discovery engine, which it refers to as an Integrated Discovery Engine, to identify targets and develop small molecule new chemical entities, or NCEs, with properties that it believes could result in potentially differentiated product profiles. It has two lead product candidates under pipeline: ZN-c5, for the treatment of advanced estrogen receptor-positive, human epidermal growth factor receptor 2-negative, or ER+/HER2-, advanced or metastatic breast cancer; and ZN-c3, for the treatment of advanced solid tumors as monotherapy and ovarian cancer.
Ticker
$ZNTL
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
124
Website
ZNTL Metrics
BasicAdvanced
$135M
-
-$2.53
1.74
-
Price and volume
Market cap
$135M
Beta
1.74
52-week high
$18.07
52-week low
$1.76
Average daily volume
2.2M
Financial strength
Current ratio
7.294
Quick ratio
7.13
Long term debt to equity
11.418
Total debt to equity
12.211
Management effectiveness
Return on assets (TTM)
-25.24%
Return on equity (TTM)
-42.89%
Valuation
Price to revenue (TTM)
3.307
Price to book
0.38
Price to tangible book (TTM)
0.38
Price to free cash flow (TTM)
-0.779
Growth
Earnings per share change (TTM)
-45.08%
3-year earnings per share growth (CAGR)
-11.09%
What the Analysts think about ZNTL
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Zentalis Pharmaceuticals stock.
ZNTL Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
ZNTL Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
ZNTL News
AllArticlesVideos
ZNTL ALERT- Levi & Korsinsky Has Commenced an Investigation on Behalf of Zentalis Pharmaceuticals, Inc. Shareholders Who Lost Money
Accesswire·11 hours ago
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zentalis Pharmaceuticals, Inc. - ZNTL
Accesswire·1 day ago
Zentalis Pharmaceuticals Announces Strategic Restructuring to Support Late-Stage Azenosertib Development
GlobeNewsWire·2 days ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Zentalis Pharmaceuticals stock?
Zentalis Pharmaceuticals (ZNTL) has a market cap of $135M as of January 31, 2025.
What is the P/E ratio for Zentalis Pharmaceuticals stock?
The price to earnings (P/E) ratio for Zentalis Pharmaceuticals (ZNTL) stock is 0 as of January 31, 2025.
Does Zentalis Pharmaceuticals stock pay dividends?
No, Zentalis Pharmaceuticals (ZNTL) stock does not pay dividends to its shareholders as of January 31, 2025.
When is the next Zentalis Pharmaceuticals dividend payment date?
Zentalis Pharmaceuticals (ZNTL) stock does not pay dividends to its shareholders.
What is the beta indicator for Zentalis Pharmaceuticals?
Zentalis Pharmaceuticals (ZNTL) has a beta rating of 1.74. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.